A RANDOMIZED STUDY ANALYZING CLINICAL AND DOSIMETRIC OUTCOME IN LOCALLY ADVANCED HEAD-AND-NECK CANCER TREATED WITH CONFORMAL CHEMORADIATION WITH OR WITHOUT INDUCTION CHEMOTHERAPY

ABHISHEK BASU; BIDYUT MANDAL; ANNESHA SEN; JANMENJOY MONDAL

doi:10.22159/ajpcr.2024.v17i3.49406

Authors

ABHISHEK BASU Department of Radiotherapy, Midnapore Medical College, Midnapore, West Bengal, India.
BIDYUT MANDAL Department of Radiotherapy, Medical College Kolkata, Kolkata, West Bengal, India.
ANNESHA SEN Department of Radiotherapy, Medical College Kolkata, Kolkata, West Bengal, India.
JANMENJOY MONDAL Department of Radiotherapy, Medical College Kolkata, Kolkata, West Bengal, India.

DOI:

https://doi.org/10.22159/ajpcr.2024.v17i3.49406

Keywords:

Induction chemotherapy, Concurrent chemoradiation, Survival, Response, Locally advanced head-and-neck cancer

Abstract

Objective: Squamous cell carcinoma of the head and neck (HNSCC) represents around 10% of new cases in India annually and with a similar trend worldwide. Treatment strategies for stages III and IV HNSCC differ in view of resectability, organ preservation, and medical conditions. Induction chemotherapy (IC) followed by concomitant chemoradiation (CTRT) is widely practiced but Indian data regarding clinical outcomes in the IGRT scenario is still not promising. In this study, we tried to evaluate the dosimetric parameters, response rate, survival, and toxicities as well.

Methods: We started our study in August 2019 with Institutional Ethical Committee approval with 42 patients in the CTRT arm and 40 patients in IC+CTRT arm. Patients in the CTRT arm received radiation (66–70 Gy) with 3 weekly cisplatin 80 mg/m2. In the induction arm, 2 cycles of taxane, platinum, 5FU were given followed by concomitant radiotherapy with the same dose and cisplatin.

Results: Overall response rates (CR+PR) were 69% versus 72.5% (p=0.06). 2 years overall survival (OS) were 66.7% versus 69.5% (p=0.91). Median disease-free survival were slightly better in the IC+CTRT arm but mean OS was comparable. Mean values of clinical target volume, planning target volume, Spine Dmax, and parotid were lower in the induction arm (p<0.05). Patients with IC experienced more hematological toxicities (p<0.01).

Conclusion: IC followed by CTRT offers better dosimetric outcome, slightly better progression-free survival, with more hematological toxicities and no OS benefit.

Downloads

Download data is not yet available.

References

Globocan; 2020. Available from: https://gco.iarc.fr/today/data/ factsheets/populations/356-india-fact-sheets.pdf [Last accessed on 2023 Apr 14].

Lacas B, Carmel A, Landais C, Wong SJ, Licitra L, Tobias JS, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 107 randomized trials and 19,805 patients, on behalf of MACH-NC Group. Radiother Oncol 2021;156:281-93. doi: 10.1016/j. radonc.2021.01.013, PMID 33515668

Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf GT, Fisher SG, Hong WK, Hillman R, Spaulding M, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-90. doi: 10.1056/NEJM199106133242402, PMID 2034244

Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-8. doi: 10.1056/NEJMoa031317, PMID 14645636

Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: Preliminary results of a European organization for research and treatment of cancer phase III trial. EORTC head and neck cancer cooperative group. J Natl Cancer Inst 1996;88:890-9. doi: 10.1093/jnci/88.13.890, PMID 8656441

Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;23:8636-45. doi: 10.1200/JCO.2004.00.1990, PMID 16275937 [published correction appears in J Clin Oncol 2006;24:1015. doi: 10.1200/JCO.2006.01.903]

Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;357:1695-704. doi: 10.1056/ NEJMoa071028, PMID 17960012

Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007;357:1705-15. doi: 10.1056/ NEJMoa070956, PMID 17960013

Paccagnella A, Ghi MG, Loreggian L, Buffoli A, Koussis H, Mione CA, et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: A phase II randomized study. Ann Oncol 2010;21:1515-22. doi: 10.1093/ annonc/mdp573, PMID 20032123

Schwartz LH, Litière S, de Vries E, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1-update and clarification: From the RECIST committee. Eur J Cancer 2016;62:132-7. doi: 10.1016/j.ejca.2016.03.081, PMID 27189322

DCTD, N,N-ih, DHHS. Common Terminology Criteria for Adverse Events. Version 3.0; 2003. Available from: https://ctep.cancer.gov [Last accessed on 2023 Mar 10].

Hitt R, Iglesias L, López-Pousa A, Berrocal-Jaime A, Grau JJ, García- Girón C, et al. Long-term outcomes of induction chemotherapy followed by chemoradiotherapy vs chemoradiotherapy alone as treatment of unresectable head and neck cancer: Follow-up of the Spanish head and neck cancer group (TTCC) 2503 trial. Clin Transl Oncol 2021;23:764- 72. doi: 10.1007/s12094-020-02467-8, PMID 32797376

Takácsi-Nagy Z, Hitre E, Remenár É, Oberna F, Polgár C, Major T, et al. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stageIII-IV unresectable head and neck cancer: Results of a randomized phase II study. Strahlenther Onkol 2015;191:635-41. doi: 10.1007/ s00066-015-0829-z, PMID 25782685

Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, Adkins D, et al. Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): A randomised phase 3 trial. Lancet Oncol 2013;14:257-64. doi: 10.1016/S1470-2045(13)70011-1, PMID 23414589

Geoffrois L, Martin L, De Raucourt D, Sun XS, Tao Y, Maingon P, et al. Induction chemotherapy followed by cetuximab radiotherapy is not superior to concurrent chemoradiotherapy for head and neck carcinomas: Results of the GORTEC 2007-02 phase III randomized trial. J Clin Oncol 2018;36:3077-83. doi: 10.1200/JCO.2017.76.2591, PMID 30016178

Stromberger C, Knecht R, Raguse JD, Keilholz U, Tribius S, Busch CJ, et al. Standard or split TPF induction chemotherapy followed by bioradiation: ICRAT randomized phase II study. J Clin Oncol 2016;34:6035. doi: 10.1200/JCO.2016.34.15_suppl.6035

Tousif D, Sarathy V, Kumar R, Naik R. Randomized controlled study comparing efficacy and toxicity of weekly vs. 3-weekly induction chemotherapy in locally advanced head and neck squamous cell carcinoma. Front Oncol 2020;10:1284. doi: 10.3389/fonc.2020.01284, PMID 32850394

Rudresha AH, Chaudhuri T, Lakshmaiah KC, Babu KG, Dasappa L, Jacob LA, et al. Induction chemotherapy in technically unresectable locally advanced T4a oral cavity squamous cell cancers: Experience from a regional cancer center of South India. Indian J Med Paediatr Oncol 2017;38:490-4. doi: 10.4103/ijmpo.ijmpo_185_16, PMID 29333018

Bhide SA, Ahmed M, Barbachano Y, Newbold K, Harrington KJ, Nutting CM. Sequential induction chemotherapy followed by radical chemo-radiation in the treatment of locoregionally advanced head-and-neck cancer. Br J Cancer 2008;99:57-62. doi: 10.1038/sj.bjc.6604444, PMID 18560402

Vishak S, Rangarajan B, Kekatpure VD. Neoadjuvant chemotherapy in oral cancers: Selecting the right patients. Indian J Med Paediatr Oncol 2015;36:148-53. doi: 10.4103/0971-5851.166716, PMID 26855522

Portas J, Corrêa D, Queija D, Arantes LM, de Souza Viana LS, Carvalho AL. Effect of induction chemotherapy on swallowing in head and neck cancer patients. Asian Pac J Cancer Prev 2019;20:91-6. doi: 10.31557/APJCP.2019.20.1.91, PMID 30678386

Chen JH, Yen YC, Liu SH, Yuan SP, Wu LL, Lee FP, et al. Outcomes of induction chemotherapy for head and neck cancer patients: A combined study of two national cohorts in Taiwan. Medicine (Baltimore) 2016;95:e2845. doi: 10.1097/MD.0000000000002845, PMID 26886647

Forastiere AA, Zhang Q, Weber RS, Maor MH, Goepfert H, Pajak TF, et al. Long-term results of RTOG 91-11: A comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 2013;31:845-52. doi: 10.1200/JCO.2012.43.6097, PMID 23182993

Dietz A, Wiegand S, Kuhnt T, Wichmann G. Laryngeal preservation approaches: Considerations for new selection criteria based on the DeLOS-II trial. Front Oncol 2019;9:625. doi: 10.3389/fonc.2019.00625, PMID 31355142

Luo X, Huang X, Luo J, Xiao J, Wang K, Qu Y, et al. Induction TPF followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locally advanced hypopharyngeal cancer: A preliminary analysis of a randomized phase 2 trial. BMC Cancer 2022;22:1235. doi: 10.1186/s12885-022-10306-y, PMID 36447152